Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn

Table of Contents

September 01, 1993; Volume 44,Issue 3
  • You have access
    High affinity amylin binding sites in rat brain.
    K Beaumont, M A Kenney, A A Young and T J Rink
    Molecular Pharmacology September 1993, 44 (3) 493-497;
  • You have access
    Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells.
    K Mackie, W A Devane and B Hille
    Molecular Pharmacology September 1993, 44 (3) 498-503;
  • You have access
    Differential modulation by cyclothiazide and concanavalin A of desensitization at native alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid- and kainate-preferring glutamate receptors.
    L A Wong and M L Mayer
    Molecular Pharmacology September 1993, 44 (3) 504-510;
  • You have access
    Role of the aryl hydrocarbon receptor nuclear translocator protein in aryl hydrocarbon (dioxin) receptor action.
    M R Probst, S Reisz-Porszasz, R V Agbunag, M S Ong and O Hankinson
    Molecular Pharmacology September 1993, 44 (3) 511-518;
  • You have access
    Enhanced stimulation by ribavirin of the 5'-phosphorylation and anti-human immunodeficiency virus activity of purine 2'-beta-fluoro-2',3'-dideoxynucleosides.
    D G Johns, G S Ahluwalia, D A Cooney, H Mitsuya and J S Driscoll
    Molecular Pharmacology September 1993, 44 (3) 519-523;
  • You have access
    Molecular cloning and functional expression of a sheep A3 adenosine receptor with widespread tissue distribution.
    J Linden, H E Taylor, A S Robeva, A L Tucker, J H Stehle, S A Rivkees, J S Fink and S M Reppert
    Molecular Pharmacology September 1993, 44 (3) 524-532;
  • You have access
    Alternative transcript of the nonselective-type endothelin receptor from rat brain.
    H F Cheng, Y M Su, J R Yeh and K J Chang
    Molecular Pharmacology September 1993, 44 (3) 533-538;
  • You have access
    Characterization of guinea pig pulmonary neurokinin type 1 receptors using a novel antagonist ligand, [3H]FK888.
    K Miyayasu, J C Mak, M Nishikawa and P J Barnes
    Molecular Pharmacology September 1993, 44 (3) 539-544;
  • You have access
    Enkephalin gene transcription in bovine chromaffin cells is regulated by calcium and protein kinase A signal transduction pathways: identification of DNase I-hypersensitive sites.
    L MacArthur, K J Koller and L E Eiden
    Molecular Pharmacology September 1993, 44 (3) 545-551;
  • You have access
    Pharmacological characterization of N-substituted phenoxazines directed toward reversing Vinca alkaloid resistance in multidrug-resistant cancer cells.
    J K Horton, K N Thimmaiah, F C Harwood, J F Kuttesch and P J Houghton
    Molecular Pharmacology September 1993, 44 (3) 552-559;
  • You have access
    Rat CYP1A1 negative regulatory element: biological activity and interaction with a protein from liver and hepatoma cells.
    K Sterling, J Weaver, K L Ho, L C Xu and E Bresnick
    Molecular Pharmacology September 1993, 44 (3) 560-568;
  • You have access
    Beta 2-adrenergic receptor mutants reveal structural requirements for the desensitization observed with long-term epinephrine treatment.
    M A Proll, R B Clark and R W Butcher
    Molecular Pharmacology September 1993, 44 (3) 569-574;
  • You have access
    Dual coupling of cloned human 5-hydroxytryptamine1D alpha and 5-hydroxytryptamine1D beta receptors stably expressed in murine fibroblasts: inhibition of adenylate cyclase and elevation of intracellular calcium concentrations via pertussis toxin-sensitive G protein(s).
    J M Zgombick, L A Borden, T L Cochran, S A Kucharewicz, R L Weinshank and T A Branchek
    Molecular Pharmacology September 1993, 44 (3) 575-582;
  • You have access
    Use of chimeric muscarinic receptors to investigate epitopes involved in allosteric interactions.
    J Ellis, M Seidenberg and M R Brann
    Molecular Pharmacology September 1993, 44 (3) 583-588;
  • You have access
    Characterization of the alpha 1A-adrenoceptors of guinea pig liver membranes: studies using 5-[3H]methylurapidil.
    J A García-Sáinz and M T Romero-Avila
    Molecular Pharmacology September 1993, 44 (3) 589-594;
  • You have access
    Benzoquinoid tyrosine kinase inhibitors are potent blockers of cardiac muscarinic receptor function.
    A de S Otero and N M Sweitzer
    Molecular Pharmacology September 1993, 44 (3) 595-604;
  • You have access
    Lysophospholipid-mediated inhibition of Na+,K(+)-adenosine triphosphatase is a possible mechanism of immunosuppressive activity of cyclosporin A.
    R Anderson, M J Smit and C E Van Rensburg
    Molecular Pharmacology September 1993, 44 (3) 605-614;
  • You have access
    Characterization of endothelial cell amino acid transport systems involved in the actions of nitric oxide synthase inhibitors.
    K Schmidt, P Klatt and B Mayer
    Molecular Pharmacology September 1993, 44 (3) 615-621;
  • You have access
    3-Isobutyl-1-methylxanthine inhibits sustained calcium current independently of cyclic AMP in neuronal and endocrine cells.
    S M Simasko and S Yan
    Molecular Pharmacology September 1993, 44 (3) 622-627;
  • You have access
    Positive modulation of human gamma-aminobutyric acid type A and glycine receptors by the inhalation anesthetic isoflurane.
    N L Harrison, J L Kugler, M V Jones, E P Greenblatt and D B Pritchett
    Molecular Pharmacology September 1993, 44 (3) 628-632;
  • You have access
    Kinetic and equilibrium characterization of vesamicol receptor-ligand complexes with picomolar dissociation constants.
    G A Rogers, W D Kornreich, K Hand and S M Parsons
    Molecular Pharmacology September 1993, 44 (3) 633-641;
  • You have access
    Verapamil blocks a rapidly activating delayed rectifier K+ channel cloned from human heart.
    D Rampe, B Wible, D Fedida, R C Dage and A M Brown
    Molecular Pharmacology September 1993, 44 (3) 642-648;
  • You have access
    Transfected D2 short dopamine receptors inhibit voltage-dependent potassium current in neuroblastoma x glioma hybrid (NG108-15) cells.
    M A Castellano, L X Liu, F J Monsma, D R Sibley, G Kapatos and L A Chiodo
    Molecular Pharmacology September 1993, 44 (3) 649-656;
  • You have access
    Mapping of ligand binding sites of neuronal nicotinic acetylcholine receptors using chimeric alpha subunits.
    C W Luetje, M Piattoni and J Patrick
    Molecular Pharmacology September 1993, 44 (3) 657-666;
  • You have access
    Structural determinants of quaternary ammonium blockers for batrachotoxin-modified Na+ channels.
    G K Wang, R Simon, D Bell, W M Mok and S Y Wang
    Molecular Pharmacology September 1993, 44 (3) 667-676;
  • You have access
    Presence of alpha-cobratoxin and phospholipase A2 activity in thymopoietin preparations.
    M Quik, R G Cook, F Revah, J P Changeux and J Patrick
    Molecular Pharmacology September 1993, 44 (3) 678-679;
  • You have access
    Notice of retraction.
    R J Lukas, L Lucero, T Audhya and G Goldstein
    Molecular Pharmacology September 1993, 44 (3) 680;
  • You have access
    Notice of retraction.
    M Quik, R Afar, S Geertsen, H el-Bizri, J M Trifaro, T Audhya and G Goldstein
    Molecular Pharmacology September 1993, 44 (3) 680; DOI: https://doi.org/10.1124/mol.44.3.680-a
Back to top
PreviousNext

In this issue

Molecular Pharmacology
Vol. 44, Issue 3
1 Sep 1993
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Read
Loading
  • How Many G Protein-Coupled Receptors are Drug Targets?
  • Histamine H3 Receptor
  • Peptide Nanoformulations against the Tumor Microenvironment
  • Characterization of Vixotrigine
  • Dehydrocrenatidine Is a Novel JAK Inhibitor
More...
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics